HF Advisory Group LLC Has $1.28 Million Position in Eli Lilly and Company $LLY

HF Advisory Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 13.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,637 shares of the company’s stock after buying an additional 192 shares during the quarter. HF Advisory Group LLC’s holdings in Eli Lilly and Company were worth $1,276,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC increased its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $27,000. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $762.84 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.86. The stock has a market cap of $722.00 billion, a P/E ratio of 49.86, a price-to-earnings-growth ratio of 1.06 and a beta of 0.47. The stock’s 50-day moving average price is $739.17 and its two-hundred day moving average price is $772.98.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business earned $3.92 earnings per share. The company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. UBS Group decreased their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.